🔴 LifeMD is trading 5.8% down in pre-market after Q2 revenue miss and lower 2026 guidance

LifeMD is trading 5.8% down in pre-market at $3.41 as investors continued reacting to its August 5, 2026, second-quarter results, including a revenue miss and lowered guidance.

• Revenue was $47.3 million, below expectations.
• Adjusted EBITDA swung to an approximately $3.5 million loss, while management reduced full-year revenue guidance to $205.5 million–$212.5 million from $220 million–$230 million.
• The broader market is nearly flat, making the earnings update the clearest catalyst.